July 29, 2016: Takeda has a plan to refocus its research & development on three targeted therapeutic areas—oncology, gastroenterology and the CNS.
July 29, 2016: An interesting, and occasionally disconcerting, business model has developed in a sector of the pharma industry. For certain super-rare diseases, there seemed to be little or no incentive for drug companies to spend millions of dollars on developing a treatment.
July 29, 2016: Elizabeth Holmes, will finally get to make a formal scientific presentation after years of avoiding sharing company information with the public. But, there appears to be a snag in the plan.
July 29, 2016: It’s half-year earnings season, and four of the biggest biotech companies have released their reports. Here’s a look at Amgen, Biogen, Celgene and Gilead Sciences).